The Energy Envelope: Pacing for ME/CFS & Long COVID

No, not if exertion itself makes your symptoms worse a day or more afterward (post-exertional malaise, PEM). Pushing through and steadily building activity back up is the graded-exercise-therapy approach, and current UK clinical guidance (NICE NG206) says any programme of fixed, incremental activity increases, including graded exercise therapy, should not be offered for ME/CFS. The same PEM mechanism applies whether it shows up under an ME/CFS diagnosis or after long COVID. The safer approach is pacing: staying inside your own energy envelope with limits set by your symptoms, not a fixed schedule of doing more.

Track your resting heart rate for about a week to find your baseline, then use it to estimate a rough personal ceiling, many clinicians start with roughly (220 minus your age) times 0.6, or times 0.5 if you are more severely affected, wear a monitor with an alarm set at that number, and rest when it sounds. This threshold is a starting estimate from clinical practice (the Klimas and Sol method), not a number a clinical trial has proven is correct for you. Some clinicians instead use the Workwell Foundation's own method, resting heart rate plus about 15 beats per minute, which is typically more conservative; ask your clinician which starting point they prefer, then refine it against your own crash pattern. Some patients and clinicians report that watching a heart-rate strap closely can become its own source of anxiety, so treat the number as a guide, not a rule to obsess over.

There is no fixed timeline, and that is worth saying plainly rather than guessing at a number. Post-exertional malaise (PEM) is commonly delayed rather than immediate, often starting 24 to 72 hours after the activity that triggered it; the IOM's 2015 clinical report named this delayed pattern as a core diagnostic feature of ME/CFS. How long a crash lasts varies widely: CDC clinical guidance describes PEM lasting anywhere from a day to several weeks, and there is no reliable way to predict your own crash length in advance. If crashes are frequent or severe, that is worth raising with your clinician alongside your pacing plan, never something to push through.

Low-dose naltrexone is a real off-label option some ME/CFS specialists use, and the honest state of the evidence is thin. The largest published ME/CFS dataset is a retrospective look back at the records of 218 Finnish patients treated with LDN, in which about three quarters reported some improvement, most often in alertness and physical or mental performance. That is an open-label chart review with no placebo group, so it cannot separate the drug from normal fluctuation or from expectation. No completed randomised placebo-controlled trial of LDN exists in ME/CFS; one is underway in post-COVID fatigue. Our fibromyalgia page shows what happened when LDN was finally tested properly there: an early small trial looked promising, and every larger randomised trial since has failed to beat placebo. We do not publish a starting dose. Naltrexone is prescription-only, every low dose is compounded, and it blocks opioid painkillers, so the dose belongs to a prescriber who knows your full medication list.

There is no proven treatment for long-COVID brain fog, and anyone selling you one is ahead of the evidence. What specialist consensus guidance actually recommends is unglamorous: find and treat the things that make thinking harder and that can be treated on their own. That means being checked for orthostatic intolerance or POTS, since for many people cognition is measurably worse upright and better lying down; reviewing sleep, mood, medications, iron and thyroid; and pacing mental work the way you pace physical work, because cognitive exertion can trigger post-exertional malaise too. The practical part is accommodation rather than cure: shorter blocks, one task at a time, working reclined, writing things down, reduced hours. Supplements and nootropics marketed for brain fog have no evidence behind them in this population. Cognitive symptoms that are actively getting worse, rather than persisting, are a reason to be seen by a clinician rather than managed at home.

We cannot tell you whether you have MCAS, and we do not have a mast-cell specialist on our roster, so treat this as an honest map rather than an answer. What is established: symptoms that look like mast cell activation, such as flushing, hives, itching, new food or drug reactions, gut symptoms and sudden heart-rate surges, are reported more often by people with long COVID than by comparison groups. What is contested is whether that pattern is actually mast cell activation syndrome. Two competing sets of diagnostic criteria are in use. The stricter consensus criteria require an objective, event-linked rise in a blood marker (tryptase) rather than symptoms alone, and when people referred for suspected MCAS are assessed against those strict criteria, only a small minority meet them. So a symptom questionnaire is a reason to ask an allergist or immunologist, not a diagnosis. Do not start antihistamines or mast-cell stabilisers as a self-experiment while the question is open.

Some people with ME/CFS work, many work reduced or adjusted hours, and many are not able to work at all. Which of those you end up in is not a measure of how hard you try, and we are not going to promise you an outcome we cannot know. The UK ME/CFS guideline (NICE NG206) treats the impact on employment as substantial and asks employers and clinicians to support people with adjustments rather than expecting a return to previous hours. What tends to matter more than effort: whether the work fits inside your energy envelope, whether it can be done in short blocks, reclined, remotely or at flexible hours, and whether you get recovery time around it. Cognitive work counts as exertion. Testing your capacity by going back full-time to see what happens is the approach most likely to cause a crash. Plan any return with your clinician, ideally with an occupational health assessment, and make every increase reversible.

Sleep hygiene advice alone usually disappoints in ME/CFS because the problem is often abnormal sleep architecture, not a habit to correct. What holds up: protecting sleep regularity and avoiding sedating antihistamines, which can deepen next-day fog (grade B, pacing-adjacent). Melatonin is grade C, one small double-blind trial of melatonin plus zinc improved perceived fatigue, not sleep architecture, and needs replication; NICE guideline NG206 dropped melatonin from its 2021 'consider' list. Skip sleep-debt catch-up framing, forced early wake with bright light plus a walk, and graded exercise sold as a sleep fix, none fit a PEM presentation. Any sleep medication decision, melatonin included, belongs to a clinician familiar with ME/CFS.

Outcomes vary widely; long COVID is not automatically permanent, but it is not guaranteed to resolve either. In the RECOVER-Adult US prospective cohort (n=3,659, mostly Omicron era), among people who met the Long COVID threshold at 3 months, about 19 percent appeared to have recovered by 15 months, about 35 percent had moderate symptoms, and about 46 percent had persistent Long COVID. Separately, 14 percent of the full cohort who did not meet criteria at 3 months had worsened into Long COVID by 15 months. Grade A for 'outcomes vary widely, and worsening after apparent early improvement is documented.' We host no Long COVID specialist on our roster yet, so treat this as cohort data, not a promise; take your own trajectory to a clinician.

This is a partial answer, and we would rather say so than guess. We could not verify a credible, quantified answer about recovery from long COVID at six months, so we publish none rather than approximate one. What is supportable, drawn from NICE NG206 and AAPM&R's PASC guidance already cited on this page: there is no single universal fix. Two things hold up: pacing to avoid post-exertional malaise, and treating the specific, treatable drivers a person actually has, orthostatic intolerance or POTS, sleep, and mast-cell-type symptoms. We are withholding a recovery statistic here because we could not verify one, that is the honest position, not an oversight.